UK-wide study validates the digital version of the emPHasis-10 QOL questionnaire for pulmonary arterial hypertension patients, European Respiratory Journal, May 2025

The emPHasis-10 questionnaire, designed to reflect that lived experience, has long been a trusted tool in both clinics and studies but until now, it was only available on paper. In a new UK-wide study, researchers led by Dr. Joseph Newman and colleagues tested the first digital version of emPHasis-10 using the Atom5™ smartphone app. Their […]

UK-wide study validates the digital version of the emPHasis-10 QOL questionnaire for pulmonary arterial hypertension patients, European Respiratory Journal, May 2025 Read Post »

Impact of insurance restrictions on pulmonary arterial hypertension (PAH) therapies in the US, “Managed Healthcare Executive”, June 21, 2024

An article by Jared Kaltwasser, in Managed Healthcare executive in its latest issue, sheds light on the growing restrictions imposed by commercial insurers on treatments for pulmonary arterial hypertension. An examination of 17 major insurance plans from 2017 to 2022 showed a sharp increase in policies with at least one restriction, jumping from 38% to

Impact of insurance restrictions on pulmonary arterial hypertension (PAH) therapies in the US, “Managed Healthcare Executive”, June 21, 2024 Read Post »

TRANSLATE »
Scroll to Top